OrbiMed’s NextCure NXTC Stock Holding History

OrbiMed’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-95,100	Closed	-$548K	–	111
2025 Q1	$548K	Hold	95,100	–	–	0.01%	106
2024 Q4	$880K	Hold	95,100	–	–	0.02%	112
2024 Q3	$1.56M	Hold	95,100	–	–	0.03%	113
2024 Q2	$1.81M	Hold	95,100	–	–	0.04%	106
2024 Q1	$2.54M	Sell	95,100 -130,818	-58%	-$2.25M	0.05%	102
2023 Q4	$3.09M	Hold	225,918	–	–	0.06%	93
2023 Q3	$3.5M	Hold	225,918	–	–	0.07%	106
2023 Q2	$4.88M	Hold	225,918	–	–	0.09%	103
2023 Q1	$4.01M	Hold	225,918	–	–	0.08%	107
2022 Q4	$3.82M	Hold	225,918	–	–	0.07%	97
2022 Q3	$7.46M	Hold	225,918	–	–	0.14%	95
2022 Q2	$12.7M	Hold	225,918	–	–	0.23%	80
2022 Q1	$13.2M	Hold	225,918	–	–	0.21%	89
2021 Q4	$16.3M	Hold	225,918	–	–	0.21%	96
2021 Q3	$18.3M	Hold	225,918	–	–	0.2%	101
2021 Q2	$21.8M	Hold	225,918	–	–	0.22%	94
2021 Q1	$27.1M	Hold	225,918	–	–	0.25%	85
2020 Q4	$29.6M	Hold	225,918	–	–	0.26%	84
2020 Q3	$23.9M	Hold	225,918	–	–	0.3%	80
2020 Q2	$58.1M	Hold	225,918	–	–	0.82%	36
2020 Q1	$100M	Hold	225,918	–	–	1.69%	19
2019 Q4	$153M	Hold	225,918	–	–	2.18%	14
2019 Q3	$83.6M	Hold	225,918	–	–	1.59%	20
2019 Q2	$40.6M	Buy	+225,918	New	+$47M	0.63%	46

Other funds holding NXTC

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CPA

Cardiff Park Advisors Carlsbad, California $1.29B AUM 23.67% 1-Year Est. Return

OrbiMed's NXTC Position: Q2 2025 in Review

OrbiMed sold out of NextCure (NXTC) in Q2 2025, closing a stake of 95,100 shares — an estimated $548K sold.

OrbiMed first reported a position in NXTC in Q2 2019 and held it in 24 quarters. The position peaked at $153M in Q4 2019. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2025.

OrbiMed reported no remaining NextCure position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 95,100 NextCure shares in Q2 2025, an estimated $548K.
OrbiMed first reported a position in NextCure in Q2 2019 and held it in 24 quarters.
OrbiMed's NextCure position peaked at $153M in Q4 2019.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.